Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Culturing of ovarian carcinoma ex vivo cells in Ovarian Carcinoma Ince Medium (OCMI)

ABSTRACT: Ascites tumor cells from two donors were cultured in OCMI.

INSTRUMENT(S): Illumina HiSeq 1500

ORGANISM(S): Homo sapiens

SUBMITTER: Silke Reinartz

PROVIDER: E-MTAB-8902 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

Exome sequencing of human ex vivo ovarian cancer models with matched stromal cells

Project description:Ascites or solid tumour from patients with ovarian cancer was collected and grown in culture as ex vivo models. Each sample has a mixture of tumour and stromal cells which were separated into individual cultures. Therefore each patient has tumour and stromal cultures originating from the same tissue collection. Variant calling (exome-seq) analysis was performed on these matched models to establish tumour specific mutations. Stromal cells were used to rule out germline mutations.

2020-03-13 | E-MTAB-7225 | biostudies-arrayexpress

RNA-seq of human ex vivo ovarian cancer models with matched stromal cells

Project description:Ascites or solid tumour from patients with ovarian cancer was collected and grown in culture as ex vivo models. Each sample has a mixture of tumour and stromal cells which were separated into individual cultures. Therefore each patient has tumour and stromal cultures originating from the same tissue collection. RNA-seq was performed on these matched models to establish gene expression profiles which allow the assessment of the separation protocol and establish genes that are differentially expressed for use in future validation processes.

2020-03-13 | E-MTAB-7223 | biostudies-arrayexpress

RNA-seq of human ex vivo ovarian cancer models - part III

Project description:Ascites or solid tumour samples from patients with ovarian cancer were collected and grown in culture as ex vivo models of purified tumour cells. RNA-seq was performed on these models to establish gene expression profiles, which allow identification of genes that are differentially expressed between patients with differing tumour intrinsic properties. These samples have been interrogated for the presence of a gene expression signature indicative of sensitivity to an inhibitor of poly(ADP-ribose) glycohydrolase (PARG). These samples are processed in the same manner as previous studies: “E-MTAB-7223 - RNA-seq of human ex vivo ovarian cancer models with matched stromal cells” and “E-MTAB-10801 - RNA-seq of human ex vivo ovarian cancer models with matched stromal cells - part II” with no stromal counterparts included in this current sequencing batch.

2021-10-10 | E-MTAB-11000 | biostudies-arrayexpress

RNA-seq of human ex vivo ovarian cancer models with matched stromal cells - part II

Project description:Ascites or solid tumour from patients with ovarian cancer was collected and grown in culture as ex vivo models. Each sample has a tumour component and some samples have matched stromal cells, which were separated into individual cultures. RNA-seq was performed on these models to establish gene expression profiles, which allow the assessment of the separation protocol and identification of genes that are differentially expressed. The histological subtype from which the models were collected includes majorly high-grade serous, but also low-grade serous, clear cell and mucinous ovarian cancer. The sample subtypes have been assessed using a machine-learning based transcriptional classifier. These samples are processed in the same manner as a previous study, “E-MTAB-7223 - RNA-seq of human ex vivo ovarian cancer models with matched stromal cells”

2021-08-05 | E-MTAB-10801 | biostudies-arrayexpress

RNA-seq of effect of Lysophosphatidic acid in ovarian cancer cell line OVCAR8 and macrophage-like cell line THP-1

Project description:Ovarian carcinoma (OVCAR8) and macrophage-like cells (THP-1) were treated with LPAs to study their gene expression response.

2019-08-01 | E-MTAB-7113 | biostudies-arrayexpress

LPA treatment of Ocmi_91s ovarian carcinoma cells.

Project description:Effect of LPA-Mixture (16:0, 18:0 18:1 18:2, 20:4) and LPAR2 specific (H2L5186303) or LPAR1 specific (Ro6842262) Inh. in OC91s cells.

2023-05-01 | E-MTAB-12487 | biostudies-arrayexpress

The intercellular signaling network of ovarian cancer metastases

Project description:Primary cells from high grade serous ovarian carcinoma patients, derived from ascites and omentum were sequenced to study signaling networks.

2021-11-01 | E-MTAB-10611 | biostudies-arrayexpress

Single cell RNA-seq from 10X for a living biobank of ovarian cancer ex vivo models reveals profound mitotic heterogeneity

Project description:We validated fifteen models from “living biobank” to provide models that support interrogation of Chromosome Instability and to evaluate novel therapeutics. Single cell RNA-seq was performed on tumour and stromal cells from 4 patients with ovarian cancer to establish gene expression profile differences between the two cell types and also heterogeneity within the tumour population. The samples used were AS38b, AS59, AS74-1, AS79, they are grown in OCMI media supplemented with 5% hyclone serum (AS38, AS59) or 5% FBS (AS74, AS79) in 5% CO2 and 5% O2. At 37C

2020-01-23 | E-MTAB-8559 | biostudies-arrayexpress

MDMs Solvent, AA, IL6, AA+IL6

Project description:Monocyte derived macrophages were exposed do arachidonic acid, IL6 or both.

2020-12-10 | E-MTAB-8830 | biostudies-arrayexpress

Human monocyte derived macrophoges exposed to arachidonic acid and interferon beta

Project description:Based on the observation that arachidonic acid represses interferon beta induced transcriptional activation of hCXCL10, hIL12b and IDO1a in THP1 cells and MDMs within 3 h post treatment. This experiment was designed to find other transcripts effected in a similar fashion.

2020-12-10 | E-MTAB-8833 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data